• No#766, Tongcheng Road
    Kunshan, Jiangsu Province,China

  • 86-21-2024 2659

  • Get A Quote

        Search:        

Building Block banner
  • Building Block

    Welcome to PHARMACORE CO.,LIMITED

    　　
    PharmaCore provides custom synthesis and contract research of both catalog and non-catalog building blocks.
     
    With high quality and competitive price.
     
    Offering you the first-rate service and high-efficiency business.
     
    Air freight service: door to door services.

  • 1-(2-chlorothiazol-5-yl)ethanone

    1909130501-(2-chlorothiazol-5-yl)ethanone

  • 1-(2-ethylhexyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxonicotinonitrile

    1909130511-(2-ethylhexyl)-1,2-dihydro-6-hydroxy-4-methyl-2-oxonicotinonitrile

  • 1-(2-fluoro-5-methoxyphenyl)ethanone

    1909130521-(2-fluoro-5-methoxyphenyl)ethanone

  • 1-(2-fluoro-5-methylpyridin-3-yl)ethanone

    1909130531-(2-fluoro-5-methylpyridin-3-yl)ethanone

  • 1-(2-methoxy-4-nitrophenyl)ethanone

    1909130541-(2-methoxy-4-nitrophenyl)ethanone

  • 1-(2-methoxy-4-nitrophenyl)propan-1-one

    1909130551-(2-methoxy-4-nitrophenyl)propan-1-one

  • 1-(2-METHOXYBENZYL)PIPERIDIN-4-ONE

    1909130561-(2-METHOXYBENZYL)PIPERIDIN-4-ONE

  • 1-(2-METHOXY-BENZYL)-PIPERIDINE-4-CARBOXYLIC ACID

    1909130571-(2-METHOXY-BENZYL)-PIPERIDINE-4-CARBOXYLIC ACID

  • 1-(2-methoxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline

    1909130581-(2-methoxyethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline

  • 1-(2-METHOXY-PHENYL)-CYCLOPROPANECARBONITRILE

    1909130591-(2-METHOXY-PHENYL)-CYCLOPROPANECARBONITRILE

  • 1-(2-methoxypyridin-3-yl)ethanone

    1909130601-(2-methoxypyridin-3-yl)ethanone

  • 1-(2-methylthiazol-5-yl)propan-2-one

    1909130611-(2-methylthiazol-5-yl)propan-2-one

First Previous Page 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 Next Page Last Page Total 4598Page55170 Record

Copyright @ PHARMACORE CO.,LIMITED. Our products are listed related to patents, for research purposes only, no commercial sales.

Back to the top